P.,et al.£ºJ Gen Virol,75,341-351£¨1994£©
36)
Schinazi,R.F.,et al.£ºInternational Antiviral News,8,65-91£¨2000£©
37)
Iversen,A.K.N.et al.£ºJ Virol,70,1086-1090£¨1996£©
38)
Winters,M.A.et al.£ºJ Clin Invest,102,1769-1775£¨1998£©
39)
De Antoni,A.et al.£ºJ Infect Dis,176,899-903£¨1997£©
40)
Larder,B.A.,et al.£ºScience,269,696-699£¨1995£©
41)
Cammack,N.,et al.£ºBiochem Pharmacol,43,2059-2064£¨1992£©
42)
Hart,G.J.,et al.£ºAntimicrob Agents Chemother,36,1688-1694£¨1992£©
43)
Coates,J.A.V.,et al.£ºAntimicrob Agents Chemother,36,733-739£¨1992£©
44)
Schuurman,R.,et al.£ºJ Infect Dis,171,1411-1419£¨1995£©
45)
Tisdale,M.,et al.£ºProc Natl Acad Sci U S A,90,5653-5656£¨1993£©
46)
Back,N.K.T.,et al.£ºEMBO J,15,4040-4049£¨1996£©
47)
Maguire,M.et al.£ºAIDS,14,1195-1201£¨2000£©
48)
Kuritzkes,D.R.,et al.£ºAIDS,10,975-981£¨1996£©
49)
Tisdale,M.,et al.£ºAntimicrob Agents Chemother,41,1094-1098£¨1997£©
50)
Miller,V.,et al.£ºAIDS,12,705-712£¨1998£©
ÎÄÏ×ÕˆÇóÏÈ
¥°¥é¥¯¥½・¥¹¥ß¥¹¥¯¥é¥¤¥óÖêʽ»áÉç
¨“151-8566 –|¾©¶¼œi¹ÈÇøÇ§ñj¥ö¹È4-6-15
¥ô¥£©`¥Ö¥Ø¥ë¥¹¥±¥¢・¥«¥¹¥¿¥Þ©`・¥µ©`¥Ó¥¹
TEL£º0120-066-525£¨9£º00¡«18£º00£¯ÍÁÈÕ×£ÈÕ¼°¤Óµ±ÉçÐݘIÈÕ¤ò³ý¤¯£©
FAX£º0120-128-525£¨24•régÊܸ¶£©
ÑuÔìØœ‰Ó˜IÕߵȤÎÊÏÃûÓÖ¤ÏÃû³Æ¼°¤ÓסËù
ÑuÔìØœ‰ÓÔª
¥ô¥£©`¥Ö¥Ø¥ë¥¹¥±¥¢Öêʽ»áÉç
–|¾©¶¼œi¹ÈÇøÇ§ñj¥ö¹È4-6-15
http://glaxosmithkline.co.jp/viiv/index.html
Øœ‰ÓÔª
¥°¥é¥¯¥½・¥¹¥ß¥¹¥¯¥é¥¤¥óÖêʽ»áÉç
¨“151-8566¡¡–|¾©¶¼œi¹ÈÇøÇ§ñj¥ö¹È4-6-15 GSK¥Ó¥ë
http://jp.gsk.com
ÒÔÏÂÊÇ¡°È«ÇòÒ½Ò©¡±Ïêϸ×ÊÁÏ |
|
|